News

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...
GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...
BLENREP is the first anti-BCMA (B-cell maturation antigen) therapy approved anywhere in the world. i Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “As the second most ...
A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...
GSK plc GSK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep ...
GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of GSK’s Blenrep (belantamab mafodotin) for treating the adult ...
You can reach Andrew on Signal at drewqjoseph.45. GSK’s blood cancer drug Blenrep won regulatory approval in the U.K. on Thursday, marking the medicine’s return to the market after it was ...
on Thursday authorized GSK plc’s GSK Blenrep. Blenrep is approved for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have ...
GSK said the European Medicines Agency's committee responsible for human medicines has recommended the approval for its Blenrep drug. The U.K. pharma company on Friday said an approval decision by ...